Table 1 Grade 3 and higher treatment related adverse events

From: Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Adverse Event

Total (N = 104)

Nivo (n = 29)

Nivo+Bev (n = 45)

Nivo + Ipi (n = 30)

Grade 3+

Grade 3+

Grade 3+

Grade 3+

N

(%)

N

(%)

N

(%)

N

(%)

Any Grade 3+ Related Event

34

(33)

8

(28)

17

(38)

9

(30)

Lipase increased

15

(14)

5

(17)

5

(11)

5

(17)

Hypertension

9

(9)

0

(0)

8

(18)

1

44

Amylase increased

6

(6)

1

44

2

(4)

3

(10)

ALT increase

3

44

1

44

1

(2)

1

44

Colitis

3

44

1

44

2

(4)

0

(0)

Pneumonitis

3

44

0

(0)

3

(7)

0

(0)

Anemia

2

(2)

1

44

1

(2)

0

(0)

Fatigue

2

(2)

0

(0)

2

(4)

0

(0)

Hyperglycemia

2

(2)

0

(0)

1

(2)

1

44

Lymphocyte decrease

2

(2)

0

(0)

1

(2)

1

44

Pain

2

(2)

0

(0)

1

(2)

1

44

Pancreatitis

2

(2)

2

(7)

0

(0)

0

(0)

AST increased

1

20

1

44

0

(0)

0

(0)

Adrenal insufficiency

1

20

1

44

0

(0)

0

(0)

Anorexia

1

20

0

(0)

1

(2)

0

(0)

Appendicitis

1

20

0

(0)

1

(2)

0

(0)

Aspiration

1

20

0

(0)

0

(0)

1

44

Atrial fibrillation

1

20

0

(0)

0

(0)

1

44

Bilirubin increase

1

20

1

44

0

(0)

0

(0)

C. difficile infection

1

20

0

(0)

1

(2)

0

(0)

Calcium pyrophosphate arthropathy

1

20

0

(0)

0

(0)

1

44

Dehydration

1

20

0

(0)

1

(2)

0

(0)

Diarrhea

1

20

0

(0)

1

(2)

0

(0)

Dyspnea

1

20

0

(0)

1

(2)

0

(0)

Glycosuria

1

20

0

(0)

0

(0)

1

44

Hemoptysis

1

20

0

(0)

1

(2)

0

(0)

Hypokalemia

1

20

0

(0)

1

(2)

0

(0)

Hypophosphatemia

1

20

1

44

0

(0)

0

(0)

Hypotension

1

20

0

(0)

1

(2)

0

(0)

Insulin deficiency

1

20

0

(0)

0

(0)

1

44

Joint range of motion decreased

1

20

0

(0)

1

(2)

0

(0)

Mucositis oral

1

20

0

(0)

1

(2)

0

(0)

Nausea

1

20

0

(0)

1

(2)

0

(0)

Proteinuria

1

20

0

(0)

1

(2)

0

(0)

Rash

1

20

0

(0)

1

(2)

0

(0)

Urinary tract infection

1

20

0

(0)

1

(2)

0

(0)